Peptide intel. Daily.
LifespanningRx removes friction from peptide access — clinician oversight baked in, no inventory required.
— Longevity Technology
In AMA #83, Attia delivers a characteristically rigorous take: peptides are a real and powerful therapeutic class, but the evidence base supporting most of them in clinical practice remains narrow. Required listening before forming a view on the current hype cycle.
Peter AttiaNiagen Bioscience has introduced a prescription-only, clinician-directed telehealth platform shipping NAD+ injection kits directly to patients via licensed 503A pharmacies. The move marks a notable upgrade in access infrastructure for one of the longevity sector's most-discussed molecules.
Longevity TechnologyA new Aging Cell study links diet quality scores directly to epigenetic clock acceleration and downstream mortality risk in a large U.S. adult cohort — adding quantitative weight to the diet-as-aging-modulator hypothesis that underpins much of the longevity nutrition space.
Aging CellNew mechanistic data reframes melatonin not as a passive sleep aid but as a potential repair-oriented intervention for aging-driven testosterone decline, directly targeting senescent Leydig cells. The implications for peptide and hormone optimization protocols are worth tracking.
Aging CellA new study finds creatine supplementation stacks meaningfully on top of resistance training benefits in older adults, adding to the growing case that creatine belongs in longevity protocols well beyond the bodybuilding context.
Lifespan.ioThe dasatinib-plus-quercetin senolytic stack, widely used in longevity self-experimentation, has now been shown to cause myelin-like damage in specific mouse brain regions. This is not a reason to panic, but it is a reason to watch the human data carefully before assuming rodent-sourced protocols are clean.
Lifespan.ioThe first controlled trial combining rapamycin with exercise failed to deliver the expected synergistic geroprotective effect — but Attia argues one negative trial is insufficient to close the book on rapamycin's longevity potential, citing design limitations and the complexity of mTOR timing.
Peter AttiaResearchers have developed a vascular age estimation framework that quantifies the gap between chronological and biological vessel aging, finding it is a meaningful independent predictor of cardiovascular disease — a direct validation of the biological clock concept increasingly used in longevity medicine.
Aging CellNew data suggest that T cells retain a pro-inflammatory phenotype long after weight normalization following obesity — an epigenetic immune memory effect with serious implications for anyone assuming that weight loss alone resets metabolic and inflammatory risk.
Lifespan.ioGlycans — the sugar-molecule coating on proteins — are gaining traction as a precision readout of biological age and immune system state, with GlycanAge positioning them as a complement to DNA methylation clocks. The 25-year inflammaging research anniversary convening at Mayo Clinic underscores how mainstream this once-fringe field has become.
Longevity TechnologyChi Longevity in Singapore reflects a deliberate national convergence of preventive medicine, precision health, and policy — one of the clearest examples globally of a healthcare system structurally adapting to biological aging rather than just disease management.
Longevity TechnologyAltos Labs, the $3 billion partial reprogramming company founded in 2022, is now actively seeking a higher public profile — a signal that internal milestones are being hit and investor pressure for visibility is increasing.
Fight Aging!Plasma dilution following myocardial ischemia-reperfusion injury improved cardiac repair, heart performance, and motor endurance in aged mice — extending the therapeutic window framing around a procedure that has already attracted substantial longevity-sector interest.
Aging CellVitamin K2 extended lifespan in C. elegans by alleviating mitochondrial stress through the JNK-1/SIR-2.1/DAF-16 signaling axis — a mechanistic pathway that parallels several NAD+ and sirtuin-targeting longevity interventions currently in human use.
Aging CellCalifornia biotech Alector has terminated its PROGRESS-AD Phase 2 trial of nivisnebart after an independent data monitoring committee concluded the study was unlikely to meet its primary endpoint — the latest setback in the search for disease-modifying Alzheimer's therapies.
Longevity TechnologyAdvanced glycation end products suppress SIRT1, triggering RANKL-dependent osteoclast signaling and chondrocyte senescence — a mechanistic loop that connects dietary glycation load directly to joint aging and OA progression.
Aging Cell
